Jaime S. King
Research Subjects
Research Interests
Jaime S. King has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Katherine L. Gudiksen
Source Hlth Care Price & Competit, San Francisco, CA 94102 USA
2 shared publicationsBenjamin Moulton
Benjamin Moulton is the senior legal adviser at the Foundation for Informed Medical Decision Making, an adjunct professor of health law at the Boston University Law School, and an adjunct lecturer in health law at the Harvard School of Public Health, in Boston, Massachusetts
1 shared publicationChristopher M. Whaley
Christopher M. Whaley is an associate policy researcher at the RAND Corporation in Santa Monica, California
1 shared publicationMonica E. Smith
UCSF/UC Hastings Consortium for Law, Science and Health Policy, San Francisco, California
1 shared publicationTimothy T. Brown
Timothy T. Brown is an associate professor of health economics, School of Public Health, University of California Berkeley
1 shared publication
Latest Publications
- 3 April 2019
- Published by Taylor & Francis in Journal of Legal Medicine
- Vol. 39 (2) , 95-120
The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs
(2019). The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs. Journal of Legal Medicine: Vol. 39, Solving America’s Drug Pricing Problem, pp. 95-120.
- 3 April 2019
- Published by Taylor & Francis in Journal of Legal Medicine
- Vol. 39 (2) , 95-120
The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs
(2019). The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs. Journal of Legal Medicine: Vol. 39, Solving America’s Drug Pricing Problem, pp. 95-120.
- 1 September 2018
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 37 (9) , 1503-1508
California’s Drug Transparency Law: Navigating The Boundaries Of State Authority On Drug Pricing
The California drug transparency bill (SB-17), signed into law in October 2017, seeks to promote transparency in pharmaceutical pricing, enhance understanding about pharmaceutical pricing trends, and assist in managing pharmaceutical costs. This article examines the legal and regulatory aspects of SB-17, explores legal challenges to the law, compares it to other state efforts to address rising drug prices, and discusses how California can maximize the impact of SB-17 by coupling the law with other incentives. While SB-17 might not significantly reduce drug prices, the new law represents a meaningful step for one state seeking to negotiate the political and legal boundaries of state action to rein in drug prices.
- 1 September 2018
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 37 (9) , 1503-1508
California’s Drug Transparency Law: Navigating The Boundaries Of State Authority On Drug Pricing
The California drug transparency bill (SB-17), signed into law in October 2017, seeks to promote transparency in pharmaceutical pricing, enhance understanding about pharmaceutical pricing trends, and assist in managing pharmaceutical costs. This article examines the legal and regulatory aspects of SB-17, explores legal challenges to the law, compares it to other state efforts to address rising drug prices, and discusses how California can maximize the impact of SB-17 by coupling the law with other incentives. While SB-17 might not significantly reduce drug prices, the new law represents a meaningful step for one state seeking to negotiate the political and legal boundaries of state action to rein in drug prices.
- Open Access
- 1 January 2016
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 137 (Supplement) , S8-S15
Whole-Genome Screening of Newborns? The Constitutional Boundaries of State Newborn Screening Programs
State newborn screening (NBS) programs routinely screen nearly all of the 4 million newborns in the United States each year for ∼30 primary conditions and a number of secondary conditions. NBS could be on the cusp of an unprecedented expansion as a result of advances in whole-genome sequencing (WGS). As WGS becomes cheaper and easier and as our knowledge and understanding of human genetics expand, the question of whether WGS has a role to play in state NBS programs becomes increasingly relevant and complex. As geneticists and state public health officials begin to contemplate the technical and procedural details of whether WGS could benefit existing NBS programs, this is an opportune time to revisit the legal framework of state NBS programs. In this article, we examine the constitutional underpinnings of state-mandated NBS and explore the range of current state statutes and regulations that govern the programs. We consider the legal refinements that will be needed to keep state NBS programs within constitutional bounds, focusing on 2 areas of concern: consent procedures and the criteria used to select new conditions for NBS panels. We conclude by providing options for states to consider when contemplating the use of WGS for NBS.
- 1 January 2016
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 137 (Supplement) , S8-S15
Open AccessWhole-Genome Screening of Newborns? The Constitutional Boundaries of State Newborn Screening Programs
State newborn screening (NBS) programs routinely screen nearly all of the 4 million newborns in the United States each year for ∼30 primary conditions and a number of secondary conditions. NBS could be on the cusp of an unprecedented expansion as a result of advances in whole-genome sequencing (WGS). As WGS becomes cheaper and easier and as our knowledge and understanding of human genetics expand, the question of whether WGS has a role to play in state NBS programs becomes increasingly relevant and complex. As geneticists and state public health officials begin to contemplate the technical and procedural details of whether WGS could benefit existing NBS programs, this is an opportune time to revisit the legal framework of state NBS programs. In this article, we examine the constitutional underpinnings of state-mandated NBS and explore the range of current state statutes and regulations that govern the programs. We consider the legal refinements that will be needed to keep state NBS programs within constitutional bounds, focusing on 2 areas of concern: consent procedures and the criteria used to select new conditions for NBS panels. We conclude by providing options for states to consider when contemplating the use of WGS for NBS.
- 1 February 2013
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 32 (2) , 294-302
Group Health’s Participation In A Shared Decision-Making Demonstration Yielded Lessons, Such As Role Of Culture Change
In 2007 Washington State became the first state to enact legislation encouraging the use of shared decision making and decision aids to address deficiencies in the informed-consent process. Group Health volunteered to fulfill a legislated mandate to study the costs and benefits of integrating these shared decision-making processes into clinical practice across a range of conditions for which multiple treatment options are available. The Group Health Demonstration Project, conducted during 2009-11, yielded five key lessons for successful implementation, including the synergy between efforts to reduce practice variation and increase shared decision making; the need to support modifications in practice with changes in physician training and culture; and the value of identifying best implementation methods through constant evaluation and iterative improvement. These lessons, and the legislated provisions that supported successful implementation, can guide other states and health care institutions moving toward informed patient choice as the standard of care for medical decision making.
- 1 February 2013
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 32 (2) , 294-302
Group Health’s Participation In A Shared Decision-Making Demonstration Yielded Lessons, Such As Role Of Culture Change
In 2007 Washington State became the first state to enact legislation encouraging the use of shared decision making and decision aids to address deficiencies in the informed-consent process. Group Health volunteered to fulfill a legislated mandate to study the costs and benefits of integrating these shared decision-making processes into clinical practice across a range of conditions for which multiple treatment options are available. The Group Health Demonstration Project, conducted during 2009-11, yielded five key lessons for successful implementation, including the synergy between efforts to reduce practice variation and increase shared decision making; the need to support modifications in practice with changes in physician training and culture; and the value of identifying best implementation methods through constant evaluation and iterative improvement. These lessons, and the legislated provisions that supported successful implementation, can guide other states and health care institutions moving toward informed patient choice as the standard of care for medical decision making.
- 31 October 2012
- Published by Springer Nature in Nature
- Vol. 491 (7422) , 33-34
Politics and fetal diagnostics collide
- 31 October 2012
- Published by Springer Nature in Nature
- Vol. 491 (7422) , 33-34
Politics and fetal diagnostics collide